May 11, 2026 —
Fractyl Health has received Clinical Trial Application authorization in the Netherlands to initiate a first-in-human Phase 1/2 study of RJVA-001, an investigational AAV-based GLP-1 gene therapy for patients with obesity and type 2 diabetes. Fractyl believes RJVA-001 is the first AAV gene therapy candidate to enter clinical development for type 2 diabetes, marking a notable step for genetic medicine beyond traditional rare disease indications.
RJVA-001 is designed as a one-time, beta-cell–targeted gene therapy intended to enable nutrient-responsive, physiologic GLP-1 expression within the pancreas. Unlike conventional GLP-1 receptor agonists, which require chronic systemic exposure through repeated dosing, RJVA-001 aims to support meal-responsive GLP-1 production at the source of metabolic regulation. The therapy is delivered through endoscopic ultrasound-guided intrapancreatic infusion, targeting pancreatic beta cells directly.
The open-label Phase 1/2 trial will include three escalating dose cohorts, followed by an optional expansion cohort of up to 20 additional participants treated at the selected optimal dose. Participants will undergo a GLP-1 washout before receiving RJVA-001 and will be monitored for 12 months for safety, glucose control, immune response, and GLP-1 expression, with long-term follow-up planned for up to five years. Primary endpoints include safety and tolerability, while secondary endpoints will evaluate preliminary efficacy using continuous glucose monitoring measures such as time-in-range and broader glycemic control metrics.
Fractyl expects to dose the first patient and report preliminary data in the second half of 2026, pending site activation. The company has also submitted a clinical trial application in Australia, with regulatory feedback expected in the third quarter of 2026. In the United States, RJVA-001 remains in preclinical development, and no Investigational New Drug application has yet been filed with the FDA.
The program reflects a broader effort to rethink GLP-1 therapy by moving from chronic pharmacologic dosing toward durable, localized metabolic gene therapy. If successful, RJVA-001 could represent a new therapeutic model for type 2 diabetes and obesity, where an AAV-based approach is used to produce physiologic GLP-1 expression in response to meals. However, as a first-in-human program, key questions remain around safety, dose control, durability, immune response, reversibility, and whether pancreas-targeted AAV delivery can achieve meaningful metabolic benefit without unacceptable risk.
